Gloucester, United Kingdom

Roger Aston

USPTO Granted Patents = 17 

Average Co-Inventor Count = 2.2

ph-index = 10

Forward Citations = 693(Granted Patents)


Location History:

  • Malmesbury, GB (1996)
  • Wiltshire, GB (1996 - 2001)
  • Gloucester, GB (1997 - 2009)

Company Filing History:


Years Active: 1996-2009

Loading Chart...
17 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Roger Aston

Introduction

Roger Aston is a notable inventor based in Gloucester, GB. He has made significant contributions to the field of biotechnology, particularly in the development of ligands that interact with tumor necrosis factor alpha (TNF). With a total of 17 patents to his name, Aston's work has the potential to impact cancer treatment and therapeutic strategies.

Latest Patents

Aston's latest patents focus on tumor necrosis factor binding ligands. The first patent describes ligands that bind to human TNF in a way that modifies its biological activity. This binding inhibits the induction of fibrin deposition in tumors and the endothelial procoagulant activity of TNF, while leaving the receptor binding activities on tumor cells unaffected. The ligands are preferably monoclonal antibodies or F(ab) fragments. The second patent relates to cell lines that produce these ligands, enhancing tumor regression activities while maintaining cytotoxicity and receptor binding activities on tumor cells.

Career Highlights

Throughout his career, Roger Aston has worked with various companies, including Arana Therapeutics Limited and Peptech Limited. His experience in these organizations has contributed to his expertise in the field of biotechnology and patent development.

Collaborations

Some of Aston's notable coworkers include Deborah Ann Rathjen and Anders Jorgen Andersen. Their collaborative efforts have likely played a role in advancing the research and development of innovative therapeutic solutions.

Conclusion

Roger Aston's contributions to the field of biotechnology, particularly through his patents on tumor necrosis factor binding ligands, highlight his innovative spirit and dedication to improving cancer treatment. His work continues to inspire advancements in therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…